Objective: To explore the efficacy of terbutaline combined with budesonide and formoterol in the treatment of acute asthma attack. Methods: From August 2023 to July 2024, 86 patients with acute asthma attack in our hospital were selected as the study objects. According to random number table method, the patients were divided into control group and observation group, with 43 cases in each group. The control group was treated with budesonide and formoterol. Observation group was treated with terbutaline on the basis of control group. The clinical efficacy, serum factor [Soluble costimulatory molecules B7 Homolog 2 (sB7-H2), Interleukin-6 (IL-6), thromboxane (TXB2)] level and the occurrence of adverse reactions were analyzed and compared between the two groups. Results: The total effective rate of observation group was significantly higher than that of control group (P < 0.05). After treatment, the levels of sB7-H2, IL-10 and TXB2 in both groups were significantly decreased compared with before treatment, and the levels of sB7-H2, IL-10 and TXB2 in the observation group were significantly decreased compared with the control group (P < 0.05). During the treatment period, no serious adverse reactions occurred in the observation group and the control group. Conclusion: Terbutaline combined with budesonide and formoterol in the treatment of acute asthma attack can improve the therapeutic effect and reduce the inflammatory response of the body, with high safety.